Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Beeh, Kai Michael ^a   Beier, Jutta ^a   Donohue, James F ^b  

^a Institut fur Atemwegsforschung INSAF   (Germany)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Blinded; Blinding; COPD; Indacaterol; Open label; Randomisation; Tiotropium

Indexed keywords

FORMOTEROL; INDACATEROL; PLACEBO; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; SCOPOLAMINE DERIVATIVE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COPD EXACERBATION; COUGHING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED DENTISTRY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH PROGRAM; HUMAN; META ANALYSIS; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); POWDER INHALER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOM; TRANSITION DYSPNEA INDEX; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTICLE; COMPARATIVE STUDY; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; METHODOLOGY; OUTCOME ASSESSMENT; PREVALENCE; SINGLE BLIND PROCEDURE;

BIAS (EPIDEMIOLOGY); BRONCHODILATOR AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SCOPOLAMINE DERIVATIVES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84862517875     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-52     Document Type: Review

References (45)

1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:c869. 10.1136/bmj.c869, 2844943, 20332511.
2. ICH Harmonised tripartite Guideline (ICH E9) Statistical principles for clinical trials 1998, ICH Harmonised tripartite Guideline (ICH E9).
3. CH Harmonised tripartite Guideline (ICH E10) Choice of control group and related issues in clinical trials 2000, CH Harmonised tripartite Guideline (ICH E10).
4. Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis 2008, 3:763-770. 2650591, 19281091.
5. Chow S-C, Liu J-P. Design and Analysis of Clinical Trials: Concepts and Methodologies, 2nd ed 2004, John Wiley & Sons, Inc, Hoboken NJ.
6. Büller HR, Halpern JL, Bounameaux H, Prins M. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. J Thromb Haemost 2008, 6:227-229.
7. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design of intervention trials. Blood Press 1992, 1:113-119. 10.3109/08037059209077502, 1366259.
8. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Updated 2010) http://www.goldcopd.com, Global Initiative for Chronic Obstructive Lung Disease (GOLD).
9. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, . INHANCE Study Investigators Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162. 10.1164/rccm.200910-1500OC, 20463178, INHANCE Study Investigators.
10. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, Kramer B, . INTIME study investigators (INdacaterol & TIotropium: Measuring Efficacy) Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 2010, 11:135. 10.1186/1465-9921-11-135, 2964613, 20920365, INTIME study investigators (INdacaterol & TIotropium: Measuring Efficacy).
11. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B, . on behalf of the INTENSITY study investigators Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011, 38:797-803. 10.1183/09031936.00191810, 21622587, on behalf of the INTENSITY study investigators.
12. Global initiative for chronic obstructive lung disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Updated 2005). Global initiative for chronic obstructive lung disease (GOLD).
13. Global initiative for chronic obstructive lung disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Updated 2006) http://www.goldcopd.com, Global initiative for chronic obstructive lung disease (GOLD).
14. Global initiative for chronic obstructive lung disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Updated 2007). Global initiative for chronic obstructive lung disease (GOLD).
15. Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N. Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities. Pneumologie 2006, 60:341-346. 10.1055/s-2005-919145, 16761228.
16. Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care-the SPiRiva Usual CarE (SPRUCE) study. Respir Res 2007, 8:45. 10.1186/1465-9921-8-45, 1913915, 17605774.
17. Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 2008, 17:169-175. 10.3132/pcrj.2008.00037, 18536860.
18. Moita J, Barbara C, Cardoso J, Costa R, Sousa M, Ruiz J, Santos ML. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 2008, 21:146-151. 10.1016/j.pupt.2007.04.003, 17693107.
19. Verkindre C, Bart F, Aguilaniu B, Fortin F, Guérin JC, Le Merre C, Iacono P, Huchon G. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006, 73:420-427. 10.1159/000089655, 16484769.
20. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005, 143:317-326.
21. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003, 58:399-404. 10.1136/thorax.58.5.399, 1746668, 12728159.
22. Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008, 3:301-310. 2629970, 18686739.
23. Chan CK, Maltais F, Sigouin C, Haddon JM, Ford GT. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007, 14:465-472. 2677771, 18060091.
24. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224. 10.1183/09031936.02.00269802, 11866001.
25. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554. 10.1056/NEJMoa0805800, 18836213.
26. Committee for proprietary medicinal products (CPMP) Points to consider in on clinical investigations of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD) 1999, www.ema.europa.eu/pdfs/human/ewp/056298en.pdf, Committee for proprietary medicinal products (CPMP).
27. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
28. Jones PW. St. George's Respiratory Questionnaire: MCID. J COPD 2005, 2:75-79.
29. Yorgancioǧlu A, Mahler DA, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium. Poster presented at the European Respiratory Society Conference 2009, Abstract: 2028, Vienna, Austria.
30. Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir Med 2005, 99(Suppl B):S11-S18.
31. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751-758. 10.1378/chest.85.6.751, 6723384.
32. Witek TJ, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003, 21:267-272. 10.1183/09031936.03.00068503a, 12608440.
33. Mahler DA, Witek TJ. The MCID of the transition dyspnea index is a total score of one unit. J COPD 2005, 2:99-103.
34. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995, 273:408-412. 10.1001/jama.1995.03520290060030, 7823387.
35. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998, 352:609-613. 10.1016/S0140-6736(98)01085-X, 9746022.
36. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001, 135:982-989.
37. Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess 2003, 7:1-76.
38. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 2002, 287:2973-2982. 10.1001/jama.287.22.2973, 12052127.
39. Als-Nielsen B, Chen W, Lotte Gluud L, Siersma V, Hilden J, Gluud C. Are trial size and reported methodological quality associated with treatment effects? Observational study of 523 randomised trials 2004, 12th Cochrane Colloquium, Ottawa, Canada, http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/view/2616.
40. Als-Nielsen B, Lotte Gluud L, Gluud C. Methodological quality and treatment effects in randomised trials: a review of six empirical studies 2004, 12th Cochrane Colloquium, Ottawa, Canada, http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/view/2594.
41. Moses LE. Measuring effects without randomized trials? Options, problems, challenges. Med Care 1995, 33(Suppl):AS8-AS14.
42. Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 1998, 317:1185-1190. 10.1136/bmj.317.7167.1185, 28700, 9794851.
43. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000, 342:1878-1886. 10.1056/NEJM200006223422506, 10861324.
44. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008, 336:601-605. 10.1136/bmj.39465.451748.AD, 2267990, 18316340.
45. American Thoracic Society/European Respiratory Society (ATS/ERS) Series ATS/ERS Task Force: Standardisation of lung function testing. Eur Respir J 2005, 26:153-968. Brusasco V, Crapo R, Viegi G, 10.1183/09031936.05.00034505, 15994402, American Thoracic Society/European Respiratory Society (ATS/ERS) Series.